Safety and Efficacy of Ademetionine in Patients With Obstructive Hypertrophic Cardiomyopathy: A Multicenter, Double-Blind, Randomized Controlled, Phase 2 Study

This study is a multicenter, double-blind, randomized controlled Phase 2 trial designed to evaluate the safety and efficacy of Ademetionine in patients with obstructive hypertrophic cardiomyopathy (oHCM). The study will recruit patients with oHCM who, under double-blind conditions, will be randomly assigned to either the Ademetionine group or the placebo group. Follow-up visits will be conducted every 4 weeks until 16 weeks from baseline. After 16 weeks, the study will evaluating the effect of Ademetionine on exercise capacity, heart failure symptoms, cardiac structure and function, and quality of life, as well as safety and tolerability of Ademetionine in this patient population.

Start Date01 Jan 2026

Sponsor / Collaborator

National Center for Cardiovascular Diseases

ChiCTR2600116322

/ RecruitingNot ApplicableIIT

Intervention Strategy of Electro-ultrasound Therapy Combined with Probiotics for Regulating Diminished Ovarian Reserve Function

Start Date01 Jan 2026

Sponsor / Collaborator

Rugao People's Hospital

ChiCTR2500114078

/ Not yet recruitingNot ApplicableIIT

A randomized, open-label, single-dose, two-formulation, two-sequence, two-period, two-way crossover bioequivalence study to evaluate the bioequivalence of a single oral dose of the test formulation of upadacitinib extended-release tablets and the reference formulation of upadacitinib extended-release tablets (trade name: RINVOQ®/Rifu®) under postprandial conditions in healthy Chinese subjects.

Start Date05 Dec 2025

Sponsor / Collaborator-

100 Clinical Results associated with Ademetionine 1,4-Butanedisulfonate

100 Translational Medicine associated with Ademetionine 1,4-Butanedisulfonate

100 Patents (Medical) associated with Ademetionine 1,4-Butanedisulfonate

8,353

Literatures (Medical) associated with Ademetionine 1,4-Butanedisulfonate

01 Feb 2026·JOURNAL OF NUTRITION

Sialic Acid Supplementation in Perinatal Mice Attenuates Gestational Diabetes Mellitus–Induced Liver Injury in Offspring at Early Adulthood

Article

Author: Hao, Huilei ; Wang, Ying ; Li, Lemei ; Wu, Jinyang ; Hou, Shaoying

BACKGROUND:

Gestational diabetes mellitus (GDM) is prone to induce hepatic injury in offspring. Sialic acid (SA) exhibits hepatoprotective effects, whereas its potential against GDM-induced liver injury in offspring remains unclear.

OBJECTIVES:

The present study aimed to investigate the hepatoprotective effects of maternal SA supplementation in GDM-exposed offspring and to explore its underlying mechanisms.

METHODS:

C57BL/6J mice were divided into 3 groups: a control (NC-m) group, a gestational diabetes mellitus (GDM-m) group, and a gestational diabetes mellitus plus SA (GDM+SA-m) group. The GDM-m group was induced using a high-fat diet combined with intraperitoneal streptozotocin injection. The GDM+SA-m group was administered N-glycolylneuraminic acid (Neu5Ac), human milk SA, via intragastric gavage at a dose of 50 mg/kg during pregnancy and lactation. Offspring from 3 groups were fed a control diet until 8 wk of age, with 20, 20, and 19 in the NC-o, GDM-o, and GDM+SA-o groups, respectively. Liver was obtained and analyzed for hematoxylin and eosin staining, aspartate aminotransferase and alanine aminotransferase, oxidative stress markers, inflammatory cytokines, and nontargeted metabolomics.

RESULTS:

Compared with the NC group, GDM significantly elevated liver transaminase levels and increased inflammatory and oxidative stress in offspring mice, with more pronounced effects observed in males. SA intervention partially attenuated this damage. Concurrently, metabolomic analysis revealed that SA significantly regulated lipid metabolism and taurine/hypotaurine pathways.

CONCLUSIONS:

The results suggested that maternal SA intervention ameliorated GDM-induced offspring liver injury, potentially by regulating hepatic lipid and taurine/hypotaurine metabolism, providing a novel mechanistic insight for early-life intervention in GDM.

09 Jan 2026·MEDICINE

Acute hepatitis of unknown origin in 38-year-old man: A case report

Article

Author: Zasheva, Anelia ; Komitov, Dimitar ; Marinova, Cvetelina ; Todovichin, Donika ; Mihaylova-Garnizova, Raynichka ; Trifonov, Petar ; Nikolov, Rosen

Rationale::

Acute hepatitis of unknown origin represents a diagnostic and therapeutic challenge, particularly when common viral, autoimmune, and toxic causes of acute liver injury are excluded.

Patient concerns::

We report a case of an adult male. He presents with general fatigue, jaundice, fever, abdominal discomfort. Laboratory findings of severe acute hepatitis and extremely elevated transaminases.

Diagnoses::

Full laboratory, serological, and toxicological tests ruled out viral, autoimmune, and drug-induced hepatitis. Metabolic disorders such as Wilson disease and hemochromatosis were also excluded.

Interventions::

Supportive therapy consisting of intravenous glucose solutions, silymarin, vitamin C, and ademetionine was initiated.

Outcomes::

The patient had rapid clinical improvement, with normalization of liver enzymes at 1-month follow-up.

Lessons::

This case shows the importance of a systematic diagnostic approach in acute hepatitis of unknown origin. It suggests that, in adult patients, conservative management with supportive therapy may lead to full recovery despite severe biochemical abnormalities.

01 Jan 2026·JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

γ-cyclodextrin based metal organic frameworks as micellar electrokinetic chromatography additive for the chiral separation of dansylated amino acids

Article

Author: Yu, Zexi ; Qiao, Juan ; Zhang, Rongyue ; Wang, Min ; Zhu, Xiaotong ; Zhang, Yan ; Li, Nan

A strategy utilizing oriented γ-cyclodextrin-based metal organic frameworks (γ-CD-MOFs) as chiral additives in micellar electrokinetic chromatography (MEKC) is presented for enhanced enantioseparation of dansylated D,L-amino acids (Dns-D,L-AAs). Its core innovation resides in the fixed orientation of γ-CD within the MOFs structure. This unique characteristic facilitates a shift in chiral recognition from "random interactions" to a "directional and highly efficient recognition" process, thereby substantially enhancing the resolution of chiral separation while overcoming the limitations of free γ-CD, including unstable interactions and poor reproducibility. Systematic optimization of SDS concentration (9.0 mM), γ-CD-MOFs concentration (16.0 mM), and buffer pH (9.5) yielded a maximum resolution (R_s) of 2.2, representing a 50 % improvement over traditional γ-CD. Under these conditions, 14 pairs of Dns-D,L-AAs achieved baseline separation, with 4 additional pairs showing partial separation. Quantitative validation for D,L-methionine (D,L-Met) demonstrated excellent linearity (19.8-1500 μM, r² = 0.999), low limits of detection (6.6 μM) and quantitation (19.8 μM), and high stability (relative standard deviations <5 %). Application to rat plasma samples revealed peak concentration (C_max) of D,L-Met at 90 min post-injection, highlighting its utility in pharmacokinetic studies of amino acid-derived prodrugs (e.g., S-adenosylmethionine). This work introduces oriented γ-CD-MOFs as a transformative chiral additive in MEKC, offering superior selectivity and reproducibility for pharmaceutical and biomedical analyses.

News (Medical) associated with Ademetionine 1,4-Butanedisulfonate

23 Aug 2024

·pharma.economictimes.indiatimes.com

Govt bans 156 medicines including antibiotics, painkillers, multivitamins: Here is the full list

New Delhi: In a significant move aimed at safeguarding public health, the Indian government has banned 156 fixed-dose combination (FDC) drugs, including a variety of antibiotics, painkillers, multivitamins, and medications for treating fever and hypertension. This decision marks the largest crackdown on FDCs since 2016, when 344 such drugs were prohibited. The Union Ministry of Health and Family Welfare issued a gazette notification on Thursday, officially prohibiting the manufacture, sale, and distribution of the banned FDCs. The ban was based on the recommendations of an expert panel that reviewed a total of 324 FDCs. Impact on Pharmaceutical Industry The banned FDCs include popular combinations such as mefenamic acid and paracetamol injections, commonly used for pain relief and fever, and omeprazole magnesium with dicyclomine HCl, used to treat abdominal pain. The ban is expected to impact major pharmaceutical companies, including Sun Pharmaceuticals, Cipla, Dr. Reddy's Laboratories, Torrent Pharmaceuticals, and Alkem Laboratories. Fixed Dose Combinations Drug Banned List Here is a table listing all 156 banned Fixed Dose Combinations (FDCs) SN Fixed Dose Combination (FDC) 1 Amylase + Protease + Glucoamylase + Pectinase + Alpha Galactosidase + Lactase + Beta-Gluconase + Cellulase + Lipase + Bromelain + Xylanase + Hemicellulase + Malt diastase + Invertase + Papain 2 Antimony Potassium Tartrate + Dried Ferrous Sulphate 3 Benfotiamine + Silymarin + L-Ornithine L-aspartate + Sodium Selenite + Folic acid + Pyridoxine hydrochloride 4 Bismuth Ammonium Citrate + Papain 5 Cyproheptadine HCl + Thiamine HCl + Riboflavine + Pyridoxine HCl + Niacinamide 6 Cyproheptadine Hydrochloride + Tricholine Citrate + Thiamine Hydrochloride + Riboflavine + Pyridoxine Hydrochloride 7 Rabeprazole Sodium (As enteric coated tablet) + Clidinium Bromide + Dicyclomine HCl + Chlordiazepoxide 8 Fungal Diastase + Papain + Nux vomica Tincture + Cardamom Tincture + Casein Hydrolysed + Alcohol 9 Mefenamic Acid + Paracetamol Injection 10 Omeprazole Magnesium + Dicyclomine HCl 11 S-adenosyl methionine + Metadoxine + Ursodeoxycholicacid BP + L-Methylfolate Calcium eq. to L- Methylfolate + Choline bitartratee + Silymarin + L-ornithine Laspartate + Inositol + Taurine 12 Silymarin + Thiamine Mononitrate + Riboflavin + Pyridoxine HCl + Niacinamide + Calcium pantothenate + Vitamin B12 13 Silymarin + Pyridoxine HCl + Cyanocobalamin + Niacinamide + Folic Acid 14 Silymarin + Vitamin B6 + Vitamin B12 + Niacinamide + Folic acid + Tricholine Citrate 15 Sodium Citrate + Citric Acid Monohydrate Flavored with Cardamom Oil, Caraway Oil, Cinnamon Oil, Clove Oil, Ginger Oil + Alcohol 16 Sucralfate + Acelofenac 17 Sucralfate + Domperidone + Dimethicone 18 Sucralfate + Domperidone 19 Tincture Ipecacuanha + Tincture Urgenia + Camphorated Opium Tincture + Aromatic Spirit of Ammonia + Chloroform + Alcohol 20 Ursodeoxycholic Acid + Metformin HCl 21 Weak Ginger tincture + Aromatic Spirit of Ammonia + Peppermint Spirit + Chloroform + Sodium Bicarbonate + Compound Cardamom + Alcohol 22 Sucralfate + Pantoprazole Sodium + Zinc Gluconate + Light Magnesium Carbonate 23 Aloe + Vitamin E Soap 24 Povidone Iodine+ Metronidazole + Aloe 25 Azelaic acid + Tea Tree Oil + Salicylic acid + Allantoin + Zinc oxide + Aloe vera + Jojoba oil + Vitamin E + Soap noodles 26 Azithromycin + Adapalene 27 Calamine + Aloes + Allantoin 28 Calamine + Diphenhydramine Hydrochloride + Aloe + Glycerine + Camphor 29 Chlorphenesin + Zinc oxide + Starch 30 Clindamycin Phosphate + Zinc acetate 31 Gamma Benzene Hexachloride + Benzocaine 32 Glucosamine hydrochloride + Diacerein + Menthol + Camphor + Capsaicin 33 Hydroxyquinone 2.0%w/w + Octyl Methoxycinnamate 5.0% w/w + Oxybenzone 30 % w/w 34 Ketoconazole +Zinc Pyrithione +D-Panthenol +Tea Tree Oil +Aloes 35 Ketoconazole +Aloe vera+ Vitamin A Acetate 36 Ketoconazole +Aloes + ZPTO 37 Kojic Acid +Arbutin +Octinoxate +Vitamin E + Mulberry 38 Lornoxicam +capsaicin +menthol+ camphor 39 Lornoxicam + Thiocolchicoside +Oleum Lini +Menthol + Methyl salicylate 40 Menthol + Aloe vera Topical Spray 41 Menthol +Lignocaine HCl +Aloe vera gel +Clotrimazole +Diphenhydramine 42 Miconazole nitrate + Gentamicin + Fluocinolone Acetonide +Zinc Sulphate 43 Miconazole +Tinidazole 44 Minoxidil +Aminexil+ Alcohol 45 Minoxidil +Azelaic acid + saw palmetto 46 Minoxidil +Aminexil 47 Pine Bark extract+ Kojic acid +Sodium Ascorbyl Phosphate 48 Povidone Iodine +Tinidazole +Zinc sulphate 49 Povidone Iodine + Ornidazole + Dexpanthenol 50 Salicyclic acid +Aloe vera+ Allantoin +D-Panthenol 51 Silver sulphadiazine +Chlorhexidine Gluconate solution +Allantoin + Aloe vera gel +Vitamin E acetate 52 Sodium salicylate + Zinc gluconate + Pyridoxine HCl 53 Tetracycline + Colistin Sulphate 54 Clomiphene +Ubidecarenone 55 Combikit of Clomiphene Citrate + Estradiol Valerate 56 Flavoxate HCl +Ofloxacin 57 Clomiphene Citrate +N-Acetylcysteine 58 Primerose Oil +Cod liver oil 59 Sildenafil Citrate +Papaverine +L-Arginine 60 Tranexamic acid +Mefenamic acid + Vitamin K1 61 Divalproex Sodium +Oxcarbazepine 62 Divalproex Sodium + Levetiracitam 63 Ergotamine tartrate +Caffeine + Paracetamol +Prochlorperazine maleate 64 Piracetam + Ginkgo biloba extracts + Vinpocetin 65 Ginkgo biloba + methylcobalamin 66 Ginkgo biloba + methylcobalamin + Alpha lipoic acid +Pyridoxine HCl 67 Ginseng Extract +Dried extract of Ginkgo Biloba 68 Meclizine HCl+ Paracetamol + Caffeine 69 Nicergoline + Vinpocetine 70 Gamma Linolenic Acid + Methylcobalamin 71 Beclomethasone Dipropionate + Neomycin Sulphate + Clotrimazole + Lignocaine HCl 72 Boric acid+ Phenylephrine HCl + Naphazoline Nitrate + Menthol + Camphor 73 Naphazoline HCl + Chlorpheniramine Maleate + Zinc Sulphate + Hydroxy Propyl Methyl Cellulose 74 Chlorpheniramine Maleate + Naphazoline HCl + Zinc Sulphate + Sodium Chloride + Hydroxy Propyl Methyl Cellulose 75 Chlorpheniramine Maleate + Naphazoline HCl + Hydroxy Propyl Methyl Cellulose 76 Chlorpheniramine Maleate + Sodium Chloride + Boric Acid + Tetrahydrozoline HCl 77 Chlorpheniramine Maleate + Phenylephrine HCl + Antipyrine 78 Ketorolac Tromethamine + Chlorpheniramine Maleate + Phenylephrine HCl + Hydroxy Propyl Methyl Cellulose 79 Ketorolac Tromethamine + Flurometholone 80 Naphazoline HCl + Zinc Sulphate + Boric Acid + Sodium Chloride+ Chlorpheniramine Maleate 81 Naphazoline HCl + Hydroxy Propyl Methyl Cellulose + Boric Acid + Borax + Menthol + Camphor 82 Naphazoline HCl + Hydroxy Propyl Methyl Cellulose + Chlorpheniramine Maleate SN Fixed Dose Combination (FDC) 83 Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride + Menthol + Camphor 84 Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride + Sodium Chloride + Hydroxy Propyl Methyl Cellulose 85 Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride + Sodium Chloride + Methylparaben 86 Methenamine + Sodium Benzoate + Benzyl Alcohol 87 Paracetamol + Phenylephrine Hydrochloride + Chlorpheniramine Maleate 88 Paracetamol + Phenylephrine Hydrochloride + Chlorpheniramine Maleate + Caffeine 89 Propoxyphene + Chlorpheniramine Maleate 90 Propoxyphene + Phenylephrine Hydrochloride + Chlorpheniramine Maleate 91 Propoxyphene + Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride 92 Sodium Benzoate + Sodium Citrate + Citric Acid 93 Vitamin A Palmitate + Vitamin C + Vitamin E + Vitamin B6 + Vitamin B12 94 Vitamin A Palmitate + Vitamin C + Vitamin E + Niacinamide 95 Vitamin B6 + Vitamin B12 + Vitamin C 96 Vitamin B6 + Vitamin B12 + Niacinamide 97 Vitamin B12 + Vitamin B6 + Vitamin C + Folic Acid 98 Vitamin B12 + Vitamin B6 + Niacinamide + Folic Acid 99 Vitamin C + Vitamin E + Vitamin A + Niacinamide 100 Vitamin D + Calcium + Magnesium 101 Vitamin D + Calcium + Magnesium + Zinc 102 Calcium + Vitamin D + Vitamin K 103 Calcium + Vitamin D + Magnesium + Zinc 104 Calcium + Vitamin D + Vitamin K + Magnesium 105 Calcium + Vitamin D + Vitamin K + Magnesium + Zinc 106 Vitamin E + Vitamin A + Vitamin C + Niacinamide 107 Vitamin E + Vitamin A + Vitamin C + Folic Acid 108 Vitamin E + Vitamin A + Vitamin C + Biotin 109 Vitamin E + Vitamin A + Vitamin C + Vitamin B12 110 Vitamin E + Vitamin C + Folic Acid 111 Vitamin E + Vitamin C + Biotin 112 Vitamin E + Vitamin C + Vitamin B12 113 Vitamin E + Vitamin C + Zinc 114 Calcium + Vitamin D + Omega-3 Fatty Acids 115 Calcium + Vitamin D + Omega-3 Fatty Acids + Vitamin K 116 Calcium + Vitamin D + Omega-3 Fatty Acids + Vitamin K + Magnesium 117 Calcium + Vitamin D + Omega-3 Fatty Acids + Vitamin K + Zinc 118 Vitamin A + Vitamin C + Vitamin E + Beta-Carotene 119 Vitamin A + Vitamin C + Vitamin E + Beta-Carotene + Zinc 120 Vitamin C + Vitamin E + Beta-Carotene 121 Vitamin C + Vitamin E + Beta-Carotene + Zinc 122 Vitamin C + Vitamin E + Selenium 123 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids 124 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids + Magnesium 125 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids + Zinc 126 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids + Biotin 127 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Selenium 128 Vitamin E + Vitamin A + Vitamin C + Zinc 129 Vitamin E + Vitamin A + Vitamin C + Selenium 130 Vitamin E + Vitamin A + Vitamin C + Biotin 131 Vitamin E + Vitamin A + Vitamin C + Folic Acid + Niacinamide 132 Vitamin E + Vitamin C + Beta-Carotene + Zinc 133 Vitamin C + Vitamin E + Biotin + Folic Acid 134 Vitamin C + Vitamin E + Beta-Carotene + Folic Acid 135 Vitamin C + Vitamin E + Beta-Carotene + Selenium 136 Vitamin E + Vitamin C + Beta-Carotene + Biotin 137 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Biotin 138 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Selenium 139 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Vitamin B12 140 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Vitamin B6 141 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Folate 142 Calcium + Vitamin D + Magnesium + Vitamin K + Omega-3 Fatty Acids 143 Calcium + Vitamin D + Magnesium + Vitamin K + Biotin 144 Calcium + Vitamin D + Magnesium + Vitamin K + Selenium 145 Calcium + Vitamin D + Magnesium + Vitamin K + Vitamin B12 146 Calcium + Vitamin D + Magnesium + Vitamin K + Folate 147 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Vitamin B6 148 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Vitamin B12 149 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Folic Acid 150 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Biotin 151 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Selenium 152 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids 153 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Zinc 154 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Biotin 155 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Selenium 156 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Vitamin B12

Drug Approval

21 Aug 2023

·synapse.patsnap.com

Progress in the Research and Development of METTL3 Drug Targets

METTL3 is an RNA methyltransferase that catalyzes the methylation of RNA at N6-adenosine, making it a key player in this process. Abnormal expression of METTL3 can lead to various diseases, including cancer, cardiovascular disorders, and neurodegenerative diseases. Therefore, finding inhibitors of METTL3 could help further our understanding of the biological functions of this enzyme and aid in the development of new treatments. N6-methyladenosine (m6A) is one of the most common and abundant covalent modifications in messenger RNA. First discovered in bacterial and eukaryotic RNA back in 1958, approximately 0.1% to 0.5% of mRNA adenines are modified by m6A. In vitro data suggests that m6A modifications affect fundamental biological processes of mRNA, including expression, splicing, localization, and translation. The occurrence of m6A modifications demonstrates tissue specificity, with significant variations observed between healthy and diseased tissues. Timeline of m6A Discovery The METTL3, an RNA methyltransferase, is one of the primary enzymes catalyzing m6A modification of RNA, but not the only one. It coexists with METTL14 and Wilms Tumor 1 Associated Protein (WTAP) in the form of a heterotrimeric complex. METTL3 possesses catalytic activity, transferring methyl groups from cofactor S-adenosylmethionine to substrate RNA, while METTL14 facilitates the binding of the substrate RNA. WTAP locates the complex at a specific nuclear region and positions the RNA substrate onto the complex. METTL3 plays roles in various aspects of cancer development. Knocking out the METTL3 gene in lung cancer cell lines and Hela cells results in decreased growth, survival, and invasion of human lung cancer cells. In human bladder, the expression of METTL3 is significantly upregulated, and the knockout of METTL3 significantly reduces the proliferation, invasion, in vitro survival, and in vivo tumorigenicity of bladder cancer cells. Competitive Landscape By entering "Mettl3" into the Synapse database, the clinically relevant molecule STC-15 can be found. In addition, a batch of molecules is in the preclinical research stage, including SAM binding pocket inhibitors, conformation inhibitors, natural products, and adenine analogs. According to a review summarized by Professor Qidong You in "Drug Discovery Today", the binding pattern of METTL3-METTL14 with inhibitors can be divided into three parts: part A is the aromatic ring, part B is the connecting chain, part C is the amino hydrophobic chain. Furthermore, the available cocrystal structures of METTL3-METTL14 and its inhibitors can help rationally design new molecules. To achieve this goal, analyzing the cocrystal structures of METTL3-METTL14 and conformation inhibitors will provide new ways for the development of new tools and potential drugs. Accent Therapeutics, which is in the same field, was established in 2017 and has attracted attention from several capitals, and has had strong development momentum in recent years. The company announced in April 2020 that it completed a $63 million B round of financing to advance new precise cancer treatments for RNA modification proteins (including METTL3 and ADAR1). At present, the company has received more than $100 million in financing. In June of the same year, Accent announced a partnership with pharmaceutical giant AstraZeneca. Key DrugSTM2457 is the first METTL3 class small molecule inhibitor developed by the UK pharmaceutical company STORM THERAPEUTICS. Unlike other RNA methyltransferases, STM2457 has high specificity for METTL3 (IC50=51.7 μM). It can induce apoptosis in cells of AML patients and mouse AML models, but it does not induce apoptosis in normal non-leukemic hematopoietic cells. After treatment, it can reduce the number of human CD45 cells in the bone marrow and spleen of mice. STORM THERAPEUTICS had raised £30 million in its Series A financing and began human clinical trials for the latest generation METTL3 inhibitor, STC-15, on November 15, 2022. The study's indication is for advanced solid tumors. This study is a phase I, multi-center, open-label study with a 3+3 cohort design, expecting to recruit 66 patients. The aim is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of STC-15 in multiple escalating daily oral doses in the Q3W treatment cycle, with dose levels determined by the modified Fibonacci algorithm. The study aims to systematically assess the safety, tolerance, pharmacokinetics, and pharmacodynamics of STC-15 in adult patients with advanced malignant tumors. The dose levels further evaluated in the expanded cohort will be selected based on available PK, pharmacodynamics, target activity, efficacy, safety, and tolerability data, including long-term safety data beyond Dose Limiting Toxicity (DLT). As METTL3 is a SAM-dependent methyltransferase, the earliest prototypes of METTL3 inhibitors were structural analogues of SAM. We are still in the early stage of discovering potent and selective METTL3 inhibitors, and many biological questions about the mechanism and function of the METTL3-METTL14 complex remain unanswered. STC-15 is the only drug that has entered the clinical stage. Interruption of METTL3-METTL14 activity could potentially lead to damage to fundamental physiological processes, resulting in harmful outcomes. To thoroughly validate METTL3-METTL14 as a manageable drug target, a multi-disciplinary approach is required to further elucidate its biological function in a broader context of epitranscriptomics.

03 Apr 2023

·www.eisai.com

EISAI ENTERS INTO AGREEMENT WITH NATIONAL CANCER CENTER TO COLLABORATE ON INVESTIGATOR-INITIATED CLINICAL RESEARCH FOR ANTICANCER AGENT TAZEMETOSTAT BASED ON “PATIENT-PROPOSED HEALTHCARE SERVICES” SYSTEM

For Print（180KB） April 3, 2023 Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has entered into an agreement with the National Cancer Center to collaborate on investigator-initiated clinical research for the EZH2 inhibitor tazemetostat hydrobromide (generic name, product name “Tazverik® Tablets 200 mg”, “tazemetostat”) based on “Patient-Proposed Healthcare Services” system. This clinical research will be conducted by the National Cancer Center Hospital. The “Patient-Proposed Healthcare Services” system is a system under which medical treatment using unapproved drugs not covered by insurance is applied for to the government based on the patient's request, and is conducted as a clinical trial to confirm safety and efficacy. Under the terms of the agreement, Eisai will provide tazemetostat free of charge to the National Cancer Center Hospital as the drug to be used in “A clinical trial of Tazemetostat for pediatric and AYA* patients with malignant tumors which have no standard of care or and which is refractory to standard of care: Patients-Proposed Healthcare Service” to be conducted by the hospital under this program. Researched and developed by Eisai and Epizyme, Inc.,** an Ipsen (Headquarters: France) company, tazemetostat is a first-in-class, oral small molecule inhibitor of the epigenetic enzyme EZH2. It is one of the histone methyltransferases in the epigenetics-related protein group, and is thought to regulate the expression of cancer-related genes and suppress the growth of cancer cells by specifically targeting EZH2, which contributes to the cancer growth process.1 Eisai holds the rights for development and commercialization of tazemetostat in Japan, where it was approved for the indication of “relapsed or refractory EZH2 gene mutation-positive follicular lymphoma (only when standard treatment is not applicable)” in 2021, and manufactures and distributes the product. Eisai positions oncology as a key franchise area and aims to create innovative drugs that act towards curing cancer. Eisai is committed to expanding the potential clinical benefits of tazemetostat for cancer treatment, as it seeks to contribute to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families and healthcare professionals. * AYA (Adolescent & Young Adult): Patients between the ages of 15 and 39. ** Acquired by Ipsen in 2022 Media Inquiries: Public Relations Department, Eisai Co., Ltd. +81-(0)3-3817-5120 [Notes to editors] 1. About the “Patient-Proposed Healthcare Services” system The “Patient-Proposed Healthcare Services” system is a system that allows patients who wish to use unapproved drugs and other medications as uninsured treatment to do so promptly, based on the patient's request, while confirming the safety and efficacy of the drug and allowing access to the unapproved drugs at medical institutions close by. The objective is to accumulate data and scientific evidence for future insurance coverage. Ministry of Health, Labour and Welfare “Patient-Proposed Healthcare Services” (Moushide Ryouyou) System: https://www.mhlw.go.jp/moushideryouyou/ (Japanese only) 2. About tazemetostat hydrobromide (generic name, product name “Tazverik® Tablets 200 mg”) Tazemetostat is a first-in-class, oral small molecule inhibitor that targets EZH2 that was jointly researched and developed under the alliance agreement between Eisai and Epizyme, Inc., an Ipsen company, utilizing Epizyme, Inc.'s proprietary product platform. This agent selectively inhibits EZH2 in a competitive matter with S-adenosylmethionine (a methyl group donor) to suppress methylation of H3K27.1 Eisai is responsible for development and commercialization of this agent in Japan, where the drug was approved in June 2021 for the indication of “relapsed or refractory EZH2 gene mutation-positive follicular lymphoma (only when standard treatment is not applicable)”. Ipsen is responsible for the development and commercialization of this agent in the United States, where accelerated approval was granted for in January 2020 with the indication of “adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection”. In June of the same year, the accelerated approval was granted for this agent with the indication of “adult relapsed / refractory follicular lymphoma who had at least 2 regimens of prior treatment and whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test”, and of “adult relapsed / refractory follicular lymphoma for which there are no satisfactory alternative treatment options”. This agent is not approved outside of Japan and the United States. 3. About epigenetics Epigenetics is a branch of science that studies the mechanism for the acquired activation/inactivation of gene function and seeks to determine how gene function is inherited through cell division, irrespective of DNA base sequence alteration. Examples of modification that lead to the regulation of gene expression include methylation of DNA and modifications of histone (methylation, acetylation, phosphorylation, etc.). 4. About EZH2 EZH2 is one of the histone methyltransferases within a larger class of epigenetics-related proteins, and specifically catalyzes the methylation of histone H3 at lysine 27 (H3K27), thus controlling expression of various genes. It is indicated that an increase in methylation of H3K27 caused by EZH2 gain-of-function mutation, overexpression, or the dysfunction of the SWI/SNF (switch/sucrose non-fermenting) complex that reportedly inhibits EZH2 methylation activity, plays an important role in carcinogenesis.1 1 Sarah K. Knutson, Satoshi Kawano, Yukinori Minoshima, et al. Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma. Molecular Cancer Therapeutics. 2014 Apr; 13(4):842–854

License out/inDrug ApprovalAccelerated ApprovalClinical StudyAcquisition

100 Deals associated with Ademetionine 1,4-Butanedisulfonate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Ademetionine 1,4-Butanedisulfonate	A16AA02	DB00118

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Liver Cirrhosis, Biliary	China	Abbott Laboratories	02 Nov 2000
Cholestasis	Italy	Abbott Laboratories	01 Jan 1975

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cholestasis, Intrahepatic	Phase 3	Russia	Abbott Laboratories	01 Jun 2014
Metabolic Dysfunction Associated Steatohepatitis	Phase 3	France	Abbott Laboratories	01 Dec 2012
Metabolic Dysfunction Associated Steatohepatitis	Phase 3	Germany	Abbott Laboratories	01 Dec 2012
Metabolic Dysfunction Associated Steatohepatitis	Phase 3	Poland	Abbott Laboratories	01 Dec 2012
Metabolic Dysfunction Associated Steatohepatitis	Phase 3	Russia	Abbott Laboratories	01 Dec 2012
Liver Diseases, Alcoholic	Phase 3	United States	Abbott Laboratories	01 Sep 2005
disorder of aging	Preclinical	China	Qingdao University	01 Mar 2024
Depressive Disorder	Preclinical	United States	Meharry Medical College	13 Oct 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04623034 (Pubmed \| BMC Pharmacol Toxicol)	Phase 1	-	34	MSI-195	szktbmtpuj(wzgmdzoatz) = dtowzerqit hxjynydpci (otwsumegmu )	-	14 Dec 2020
NCT00769002 (Pro00000226, CTgov)	Not Applicable	Influenza, Human	18	Influenza Vaccine (Influenza Vaccine FluShield, FluMist)	nxgiuajkdq(clqhnhcrtj) = jewccwkrce oulywdepmr (bgspwpfpcp, twcafyxagx - yswjuewjcs) View more	-	19 Oct 2020
				flu vaccine (Cytokine Profiling FluShield, FluMist)	nxgiuajkdq(clqhnhcrtj) = fowcgrhdmj oulywdepmr (bgspwpfpcp, qosftbsdyy - ajcypfbdqb) View more
NCT00513461 (CTgov)	Phase 2	Hepatocellular Carcinoma \| Hepatitis C, Chronic	110	immunoenzyme technique+S-adenosyl-L-methionine disulfate p-toluene-sulfonate (Arm I (SAMe))	bnlztvfqld(kcqvcgnnxe) = uvkigbxvpa pkootusprs (cwkcpgadcv, 20.304) View more	-	10 Aug 2018
				placebo (Arm II (Placebo))	bnlztvfqld(kcqvcgnnxe) = ubhsglqbaj pkootusprs (cwkcpgadcv, 29.207) View more
NCT00070941 (CTgov)	Phase 2/3	Parkinson Disease	29	SAM-e (SAM-e)	nndgydbeyd(ypcqazqtpk) = gvdtbvrexp dsgadwjicm (dxbefwkawr, 4.8) View more	-	13 Jul 2016
				oral escitalopram (Escitalopram)	nndgydbeyd(ypcqazqtpk) = cvxsghgwrb dsgadwjicm (dxbefwkawr, 5.4) View more
NCT00093847 (CTgov)	Phase 2	Depressive Disorder, Treatment-Resistant	73	SAMe Tosylate (Adjunct Oral SAMe Tosylate 800mg PO BiD)	vepkjacdhf = xqoshxnmql izzaubowbn (mojyzolhyd, wvbxfbqakc - iewdmftsxt) View more	-	13 Oct 2014
				placebo (Oral Adjunct Placebo)	vepkjacdhf = bsndquqoor izzaubowbn (mojyzolhyd, askyyvjmui - bqjuxlednq) View more
AACR2014	Phase 2	Liver Cirrhosis	110	SAMe	rngosgtxnj(yixeppppno) = fddcrwuipy qsgzfbujol (mturyptvrs )	Negative	01 Oct 2014
				Placebo	rngosgtxnj(yixeppppno) = lnbvwllmoh qsgzfbujol (mturyptvrs )
NCT00762268 (CTgov)	Not Applicable	Bipolar Disorder	23	SAMe (SAMe)	ullnobknny(wwkszdoami) = zvgfogwhti ehsrmxskwz (xysknjrxuc, iyenmjzvbr - shfsjsheks) View more	-	26 Aug 2014
				Placebo (Placebo)	ullnobknny(wwkszdoami) = reuyhinwro ehsrmxskwz (xysknjrxuc, rdxutnkeuz - wolyneosmo) View more
NCT01140646 (SAMe, CTgov)	Phase 2	Hot Flashes	45	s-adenosyl-L-methionine	ujbugybtci(uqwkqyfmoj) = rxyftyjmyt icltxyshmv (oaexfrtzvo, pcmklugonf - tzntjuvkyd) View more	-	11 Apr 2014
NCT00694564 (CTgov)	Not Applicable	Abdominal Pain	8	S-adenosyl methionine (SAM-e)	jkrnjvevzc(bcfknwxszf) = smonnjhbmh mcqrigloqg (wirouvljof, 0) View more	-	13 Sep 2013
				Sam-e (Sam-e (Treatment))	yqopprybpz(vbidyqhkty) = cfxuqgznlv rumiyxqoyp (remauzoeop, erpjhrasix - wrqhwlrysj) View more
NCT00573313 (CTgov)	Phase 3	Liver Diseases, Alcoholic	94	S-adenosylmethionine (S-adenosylmethionine (SAMe))	tesfmmofue(uvejpkpzjd) = ibgpbopgnv nrgqgipziv (clieohuoao, jykpsrenmt - txwfqrlwlo) View more	-	10 Jun 2013
				Placebo (Sugar Pill)	tesfmmofue(uvejpkpzjd) = krbucaceeo nrgqgipziv (clieohuoao, dtcajiyull - zcdisyhnth) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Ademetionine 1,4-Butanedisulfonate

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation